Skip to main content
Top
Published in: Diabetologia 7/2006

01-07-2006 | Article

Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients

Authors: N. Katakami, H. Kaneto, M. Matsuhisa, T. Miyatsuka, K. Sakamoto, D. Kawamori, K. Yoshiuchi, Y. Nakamura, K. Kato, K. Yamamoto, K. Kosugi, M. Hori, Y. Yamasaki

Published in: Diabetologia | Issue 7/2006

Login to get access

Abstract

Aims/hypothesis

It has recently been shown that the soluble form of CD40 ligand (sCD40L) interacts with CD40 on vascular cells, leading to a variety of proinflammatory responses, and that serum sCD40L levels can be a predictive marker of cardiovascular events. The aim of this study was to estimate sCD40L levels in type 1 diabetic patients to examine a possible association with carotid atherosclerosis.

Subjects and methods

Human sCD40L levels in serum and intima–media thickness (IMT) of carotid artery were examined in 80 Japanese type 1 diabetic patients (27 men and 53 women, age 22.8±3.4 years (mean±SD), duration of diabetes 13.2±6.1 years) and 20 healthy age-matched non-diabetic individuals.

Results

Serum sCD40L levels were significantly (p=0.0185) higher in subjects with type 1 diabetes (2.10±1.33 ng/ml) compared with non-diabetic subjects (1.35±0.88 ng/ml). The greatest IMT (Max-IMT) and averaged IMT (Mean-IMT) were also significantly greater in patients with type 1 diabetes than in control subjects (0.73±0.14 vs 0.64±0.07 mm, p=0.0041, 0.63±0.09 vs 0.57±0.06 mm, p=0.0066, respectively). Levels of sCD40L were statistically significantly associated with Max-IMT (r=0.383, p<0.001) and Mean-IMT (r=0.275, p=0.0058). Furthermore, stepwise multivariate regression analyses demonstrated that sCD40L is a determinant of both Max- and Mean-IMT, independently of conventional risk factors.

Conclusions/interpretation

It is suggested that increased levels of serum sCD40L are associated with accelerated atherosclerotic change observed in young patients with type 1 diabetes.
Literature
1.
2.
go back to reference Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809PubMedCrossRef Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809PubMedCrossRef
3.
go back to reference Adams DH, Shaw S (1994) Leucocyte–endothelial interactions and regulation of leucocyte migration. Lancet 343:831–836PubMedCrossRef Adams DH, Shaw S (1994) Leucocyte–endothelial interactions and regulation of leucocyte migration. Lancet 343:831–836PubMedCrossRef
4.
go back to reference Lutgens E, Gorelik L, Daemen MJ, et al (1999) Requirement for CD154 in the progression of atherosclerosis. Nat Med 5: 1313–1316PubMedCrossRef Lutgens E, Gorelik L, Daemen MJ, et al (1999) Requirement for CD154 in the progression of atherosclerosis. Nat Med 5: 1313–1316PubMedCrossRef
5.
go back to reference Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394:200–203PubMedCrossRef Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394:200–203PubMedCrossRef
6.
go back to reference Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D (1995) Stimulation of CD40L with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155:4917–4925PubMed Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D (1995) Stimulation of CD40L with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155:4917–4925PubMed
7.
go back to reference Hollenbaugh D, Mischel-Petty N, Edwards CP, et al (1995) Expression of functional CD40L by vascular endothelial cells. J Exp Med 182:33–40PubMedCrossRef Hollenbaugh D, Mischel-Petty N, Edwards CP, et al (1995) Expression of functional CD40L by vascular endothelial cells. J Exp Med 182:33–40PubMedCrossRef
8.
go back to reference Aukrust P, Muller F, Ueland T, et al (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–620PubMed Aukrust P, Muller F, Ueland T, et al (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–620PubMed
9.
go back to reference Garlichs CD, Eskafi S, Raaz D, et al (2001) Patients with acute coronary syndrome express enhanced CD40 ligand/CD154 on platelets. Heart 86:649–655PubMedCrossRef Garlichs CD, Eskafi S, Raaz D, et al (2001) Patients with acute coronary syndrome express enhanced CD40 ligand/CD154 on platelets. Heart 86:649–655PubMedCrossRef
10.
go back to reference Tsakiris DA, Tschopl M, Wolf F, Labs KH, Jager KA, Marbet GA (2000) Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 11:165–173PubMedCrossRef Tsakiris DA, Tschopl M, Wolf F, Labs KH, Jager KA, Marbet GA (2000) Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 11:165–173PubMedCrossRef
11.
go back to reference Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268PubMedCrossRef Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268PubMedCrossRef
12.
go back to reference Heeschen C, Dimmeler S, Hamm CW, et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111PubMedCrossRef Heeschen C, Dimmeler S, Hamm CW, et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111PubMedCrossRef
13.
go back to reference Varo N, Vincent D, Libby P, et al (2003) Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. Circulation 107:2664–2669PubMedCrossRef Varo N, Vincent D, Libby P, et al (2003) Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. Circulation 107:2664–2669PubMedCrossRef
14.
go back to reference Harding SA, Sommerfield AJ, Sarma J, et al (2004) Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176:321–325PubMedCrossRef Harding SA, Sommerfield AJ, Sarma J, et al (2004) Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176:321–325PubMedCrossRef
15.
go back to reference Yamasaki Y, Kawamori R, Matsushima H, et al (1994) Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 43:634–639PubMedCrossRef Yamasaki Y, Kawamori R, Matsushima H, et al (1994) Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 43:634–639PubMedCrossRef
16.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
17.
go back to reference Kawamori R, Yamasaki Y, Matsushima H, et al (1992) Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 15:1290–1294PubMedCrossRef Kawamori R, Yamasaki Y, Matsushima H, et al (1992) Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 15:1290–1294PubMedCrossRef
18.
go back to reference Yamasaki Y, Kodama M, Nishizawa H, et al (2000) Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 23:1310–1315PubMedCrossRef Yamasaki Y, Kodama M, Nishizawa H, et al (2000) Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 23:1310–1315PubMedCrossRef
19.
go back to reference Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74:1399–1406PubMed Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74:1399–1406PubMed
20.
go back to reference Cipollone F, Chiarelli F, Davi G, et al (2005) Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 48:1216–1224PubMedCrossRef Cipollone F, Chiarelli F, Davi G, et al (2005) Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 48:1216–1224PubMedCrossRef
21.
go back to reference Targher G, Zoppini G (2004) Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications. Diabetes Care 27:1236–1237PubMedCrossRef Targher G, Zoppini G (2004) Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications. Diabetes Care 27:1236–1237PubMedCrossRef
22.
go back to reference Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899PubMedCrossRef Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899PubMedCrossRef
23.
go back to reference O’Leary DH, Polak JF, Kronmal RA, et al (1992) Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke 23:1752–1760PubMed O’Leary DH, Polak JF, Kronmal RA, et al (1992) Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke 23:1752–1760PubMed
25.
go back to reference Mach F, Schönbeck U, Bonnefoy J-Y, Pober JS, Libby P (1997) Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96:396–399PubMed Mach F, Schönbeck U, Bonnefoy J-Y, Pober JS, Libby P (1997) Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96:396–399PubMed
Metadata
Title
Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients
Authors
N. Katakami
H. Kaneto
M. Matsuhisa
T. Miyatsuka
K. Sakamoto
D. Kawamori
K. Yoshiuchi
Y. Nakamura
K. Kato
K. Yamamoto
K. Kosugi
M. Hori
Y. Yamasaki
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0281-9

Other articles of this Issue 7/2006

Diabetologia 7/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.